MUCOSAL PLANTIBODIES: A HUMAN ANTISPERM SIGA

粘膜植物抗体：人类抗精子 SIGA

• 批准号: 2777607
• 负责人: Kevin John Whaley
• 金额: $ 9.97万
• 依托单位: REPROTECT, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-03-01 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2777607
• 关键词: agglutination reaction; agglutinins; antibody; corn; drug design /synthesis /production; drug screening /evaluation; genetically modified plants; human tissue; immunoglobulin A; immunological substance; male; medicinal plants; molecular cloning; mucosal immunity; plant proteins; sperm; spermicide

The overall goal is to develop an antibody based, barrier contraceptive microbicide. This application is limited to the production and in vitro evaluation of a human anti-sperm secretory IgA (SigA), that is expressed at high levels in corn. SigA antibodies are non-inflammatory and the predominant isotype of antibody on mucosal surfaces, and protection generally correlates with levels of SigA antibodies in the mucus secretions of the gastrointestinal, respiratory and genitourinary tracts. The role of antibodies in immune infertility, their potency, and specificity of antibodies make their candidates for use in female controlled-barrier methods. These studies will demonstrate the feasibility of making a contraceptive plantibody in plants and provide a suitable low cost product for clinical development. PROPOSED COMMERCIAL APPLICATION: Antibody-based technology is now coming to fruition for systemic therapeutics, but eh untapped commercial applications for antibodies are in mucosal prevention. A vaginal contraceptive microbicide is one important application for mucosal antibodies, but the technology is so flexible that it is readily extended to other contraceptive and reproductive health applications or to the prevention of diseases by pathogens at other mucosal sites.

总体目标是开发一种基于抗体的屏障避孕杀菌剂。这一应用仅限于人类抗精子分泌IgA(SIgA)的生产和体外评估，该抗体在玉米中高水平表达。SIgA抗体是非炎症性的，是粘膜表面的主要同种抗体，保护作用通常与胃肠道、呼吸道和泌尿生殖道粘液分泌物中的SIgA抗体水平有关。抗体在免疫性不孕症中的作用、效力和特异性使其成为女性控制屏障方法的候选对象。这些研究将证明在植物中制造避孕植物体的可行性，并为临床开发提供合适的低成本产品。拟议的商业应用：基于抗体的技术目前正在系统疗法中取得成果，但抗体尚未开发的商业应用是在粘膜预防方面。阴道避孕杀菌剂是粘膜抗体的一个重要应用，但这项技术非常灵活，很容易扩展到其他避孕和生殖健康应用，或通过其他粘膜部位的病原体预防疾病。